SEARCH

SEARCH BY CITATION

Hall, T. L., Tell, L. A., Wetzlich, S. E., McCormick, J. D., Fowler, L. W., Pusterla, N. Pharmacokinetics of ceftiofur sodium and ceftiofur crystalline free acid in neonatal foals. J. vet. Pharmacol. Therap.34, 403–409.

Ceftiofur, a third generation cephalosporin, demonstrates in vitro efficacy against microorganisms isolated from septicemic neonatal foals. This pharmacokinetic study evaluated the intravenous and subcutaneous administration of ceftiofur sodium (5 mg/kg body weight; = 6 per group) and subcutaneous administration of ceftiofur crystalline free acid (6.6 mg/kg body weight; = 6) in healthy foals. Plasma ceftiofur- and desfuroylceftiofur-related metabolite concentrations were measured using high performance liquid chromatography following drug administration. Mean (±SD) noncompartmental pharmacokinetic parameters for i.v. and s.c. ceftiofur sodium were: AUC0[RIGHTWARDS ARROW] (86.4 ± 8.5 and 91 ± 22 h·μg/mL for i.v. and s.c., respectively), terminal elimination half-life (5.82 ± 1.00 and 5.55 ± 0.81 h for i.v. and s.c., respectively), Cmax(obs) (13 ± 1.9 μg/mL s.c.), Tmax(obs) (0.75 ± 0.4 h for s.c.). Mean (± SD) noncompartmental pharmacokinetic parameters for s.c. ceftiofur crystalline free acid were: AUC0[RIGHTWARDS ARROW] (139.53 ± 22.63 h·μg/mL), terminal elimination half-life (39.7 ± 14.7), Cmax(obs) (2.52 ± 0.35 μg/mL) and tmax(obs) (11.33 ± 1.63 h). No adverse effects attributed to drug administration were observed in any foal. Ceftiofur- and desfuroylceftiofur-related metabolites reached sufficient plasma concentrations to effectively treat common bacterial pathogens isolated from septicemic foals.